罗格列酮治疗30例2型糖尿病的临床疗效

Clinical Efficacy of Rosiglitazone in Treating 30 Type 2 Diabetes Patients

目的 :观察罗格列酮联合治疗 2型糖尿病的疗效和安全性。方法 :6 0例 2型糖尿病患者分为 2组 ,罗格列酮组 (30例 )在原治疗方案基础上联合罗格列酮 4mg,qd ,po ,对照组 (30例 )维持原治疗方案。试验历时 5 2周 ,观察空腹血糖、糖化血红蛋白 (HbA1c)、空腹胰岛素、稳态模式胰岛素抵抗指数 (HOMA -IR)和血脂的变化。结果 :罗格列酮组空腹血糖、HbA1c、空腹胰岛素和HOMA -IR治疗后较治疗前明显下降 ,分别下降了 (1.4± 1.3)mmol·L-1,(0 .8± 1.0 ) % ,(3± 6 )mU·L-1和 (1.93± 3.13) ,均P <0 .0 5 ,而对照组治疗前后的变化无显著差异 (P >0 .0 5 ) ,2组间存在显著差异 (P <0 .0 5 ) ,罗格列酮组的高密度脂蛋白 (HDL -ch)、HDL -ch总胆固醇变化水平明显高于对照组 (分别为P <0 .0 1和P <0 .0 5 )。结论 :罗格列酮可降低 2型糖尿病患者的胰岛素水平 ,改善胰岛素抵抗 ,长期、有效地控制血糖 ,并能改善脂代谢 ,减少心血管疾病的危险因素 。

Objective: To evaluate the efficacy and safety of rosiglitazone (Avendia) in combination with previous therapy in the treatment of type 2 diabetes. Methods: 60 type 2 diabetic patients were involved in this 52 week study. 30 patients were randomly divided into rosiglitazone group.They were treated with rosiglitazone 4mg,qd,po combined with previous therapy. The other 30 patients into control group。The previous therapy was maintained. Fasting plasma glucose, HbA1c,fasting insulin, Homeostasis model insulin resistance index( HOMA-IR ) and serum lipid were evaluated. Results: In rosiglitazone group, significant decrease was observed in fasting plasma glucose, HbA1c, fasting insulin and HOMA-IR[(1.4±1.3) mmol·L -1, (0.8±1.0)%,(3±6 ) mU·L -1 and(1.93±3.13) respectively,P<0.05]. There was no change of these parameters in control group. Significant difference could be observed between two groups (P<0.05).In rosiglitazone group, the change level of HDL-c and HDL-c/TC was significant higher than that in control group(P<0.01, P<0.05 respectively). Conclusion:Rosiglitazone can decrease the insulin level of type 2 diabetic patients, improve the insulin sensitivity, reach long term and efficient blood glucose control, improve lipid metabolism,reduce the risk factors of cardiovascular disease. It's effective and safe in the treatment of type 2 diabetes.